MedTrace Logo

Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia

NCT01206335 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-11-27

No results posted yet for this study

Summary

The purpose of this study is to determine whether patients with advanced cancers who receive OHR/AVR118 solution for injection into the skin can achieve improvement in quality of life. Based on a previous study in patients with AIDS, possible benefits may include improved appetite and strength; weight gain, improved mood; and decreased fatigue.

Conditions

  • Anorexia
  • Cancer Cachexia

Interventions

DRUG

OHR/AVR118

OHR/AVR118 given subcutaneously at 4mL per day

Sponsors & Collaborators

  • Ohr Pharmaceutical Inc.

    lead INDUSTRY

Principal Investigators

  • Martin Chasen, MBChB · Ottawa Hospital Cancer Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2012-12-31
Completion
2013-02-28

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01206335 on ClinicalTrials.gov